210 related articles for article (PubMed ID: 24795343)
1. Tumor-targeting properties of novel immunocytokines based on murine IL1β and IL6.
Hess C; Neri D
Protein Eng Des Sel; 2014 Jun; 27(6):207-13. PubMed ID: 24795343
[TBL] [Abstract][Full Text] [Related]
2. The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel.
Pasche N; Wulhfard S; Pretto F; Carugati E; Neri D
Clin Cancer Res; 2012 Aug; 18(15):4092-103. PubMed ID: 22693354
[TBL] [Abstract][Full Text] [Related]
3. The antibody-mediated targeted delivery of interleukin-13 to syngeneic murine tumors mediates a potent anticancer activity.
Hess C; Neri D
Cancer Immunol Immunother; 2015 May; 64(5):635-44. PubMed ID: 25722088
[TBL] [Abstract][Full Text] [Related]
4. Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation.
Frey K; Zivanovic A; Schwager K; Neri D
Integr Biol (Camb); 2011 Apr; 3(4):468-78. PubMed ID: 21225052
[TBL] [Abstract][Full Text] [Related]
5. The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer.
Hemmerle T; Neri D
Int J Cancer; 2014 Jan; 134(2):467-77. PubMed ID: 23818211
[TBL] [Abstract][Full Text] [Related]
6. The dose-dependent tumor targeting of antibody-IFNγ fusion proteins reveals an unexpected receptor-trapping mechanism in vivo.
Hemmerle T; Neri D
Cancer Immunol Res; 2014 Jun; 2(6):559-67. PubMed ID: 24795141
[TBL] [Abstract][Full Text] [Related]
7. Cloning and characterization of novel tumor-targeting immunocytokines based on murine IL7.
Pasche N; Woytschak J; Wulhfard S; Villa A; Frey K; Neri D
J Biotechnol; 2011 Jun; 154(1):84-92. PubMed ID: 21527292
[TBL] [Abstract][Full Text] [Related]
8. Tumor targeting properties of antibody fusion proteins based on different members of the murine tumor necrosis superfamily.
Hemmerle T; Hess C; Venetz D; Neri D
J Biotechnol; 2014 Feb; 172():73-6. PubMed ID: 24384233
[TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy.
Pretto F; Elia G; Castioni N; Neri D
Cancer Immunol Immunother; 2014 Sep; 63(9):901-10. PubMed ID: 24893857
[TBL] [Abstract][Full Text] [Related]
10. Novel antibody-cytokine fusion proteins featuring granulocyte-colony stimulating factor, interleukin-3 and interleukin-4 as payloads.
Schmid AS; Tintor D; Neri D
J Biotechnol; 2018 Apr; 271():29-36. PubMed ID: 29438784
[TBL] [Abstract][Full Text] [Related]
11. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
[TBL] [Abstract][Full Text] [Related]
12. Murine analogues of etanercept and of F8-IL10 inhibit the progression of collagen-induced arthritis in the mouse.
Doll F; Schwager K; Hemmerle T; Neri D
Arthritis Res Ther; 2013 Sep; 15(5):R138. PubMed ID: 24289726
[TBL] [Abstract][Full Text] [Related]
13. Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12.
Sommavilla R; Pasche N; Trachsel E; Giovannoni L; Roesli C; Villa A; Neri D; Kaspar M
Protein Eng Des Sel; 2010 Aug; 23(8):653-61. PubMed ID: 20551083
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung adenocarcinoma.
Wieckowski S; Hemmerle T; Prince SS; Schlienger BD; Hillinger S; Neri D; Zippelius A
Lung Cancer; 2015 Apr; 88(1):9-15. PubMed ID: 25682318
[TBL] [Abstract][Full Text] [Related]
15. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo.
Villa A; Trachsel E; Kaspar M; Schliemann C; Sommavilla R; Rybak JN; Rösli C; Borsi L; Neri D
Int J Cancer; 2008 Jun; 122(11):2405-13. PubMed ID: 18271006
[TBL] [Abstract][Full Text] [Related]
16. Targeted delivery of calreticulin to ED-A fibronectin leads to tumor-growth retardation.
Ziffels B; Grötsch A; Al-Bayati L; Neri D
J Biotechnol; 2019 Jan; 290():53-58. PubMed ID: 30579890
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of antibody-chemokine fusion proteins for tumor-targeting applications.
Hess C; Neri D
Exp Biol Med (Maywood); 2014 Jul; 239(7):842-852. PubMed ID: 24872435
[TBL] [Abstract][Full Text] [Related]
18. Antibody-mediated delivery of LIGHT to the tumor boosts natural killer cells and delays tumor progression.
Stringhini M; Mock J; Fontana V; Murer P; Neri D
MAbs; 2021; 13(1):1868066. PubMed ID: 33404287
[TBL] [Abstract][Full Text] [Related]
19. Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis.
Schwager K; Kaspar M; Bootz F; Marcolongo R; Paresce E; Neri D; Trachsel E
Arthritis Res Ther; 2009; 11(5):R142. PubMed ID: 19781067
[TBL] [Abstract][Full Text] [Related]
20. The antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse model.
Schwager K; Bootz F; Imesch P; Kaspar M; Trachsel E; Neri D
Hum Reprod; 2011 Sep; 26(9):2344-52. PubMed ID: 21705369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
